Last updated: August 3, 2020
The real battle against cancer is fought by physicians and patients!
Our mission is simply to provide healthcare professionals
with innovative tools that are the most reliable and effective possible.
The hPG80 blood biomarker has now been shown to be both a major weak point of cancer and a fundamental target to providing physicians with multiple solutions, now and in the future * :
In cancer, hPG80 is overexpressed in the tumor and detectable in the patient’s blood[1]. 16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date[1].
-
Cancer stem cells express elevated levels of hPG80 (circulating progastrin)[2][3].
-
Secretion of hPG80 maintain tumor-initiating and self-renewal capabilities of cancer stem cells[3].
-
hPG80 is released from the tumor and becomes detectable in the blood across all stages[3][4].
-
Plasma hPG80 is elevated in a wide range of cancer patients[5]
hPG80 is produced by all cancer cells, but in quantities 100 to 1000 times higher by cancer stem cells[2], making hPG80 the only blood biomarker that gives information on tumor activity.
BIBLIOGRAPHY
[1]. You et al, EBioMedicine, 2020 Jan;51:102574
[2]. Giraud et al, Cancer Res, 2016;76(12):3618-28
[3]. Siddheshwar et al, Gut, 2001 Jan; 48(1): 47–52
[4]. Prieur et al, Clin Cancer Res. 2017;23(17):5267–5280
[5]. Konieczkowski et al, Cancer Cell, 2018 May 14;33(5):801-815
KEY FACTS
NOW AVAILABLE TO PHYSICIANS
A NEW TOOL :
The blood test
for detection and measurement of the target hPG80
AVAILABLE ONLY ON MEDICAL PRESCRIPTION
